Datasheet for ABIN7535647

# SFTPD Protein (His tag)

Go to Product page

## Overview

| | |
|---|---|
| Quantity: | 100 µg |
| Target: | SFTPD |
| Origin: | Mouse |
| Source: | HEK-293 Cells |
| Protein Type: | Recombinant |
| Purification tag / Conjugate: | This SFTPD protein is labelled with His tag. |

## Product Details

| | |
|---|---|
| Purpose: | Recombinant Mouse Lung surfactant protein D/SFTPD Protein |
| Sequence: | AEMKSLSQRS VPNTCTLVMC SPTENGLPGR DGRDGREGPR GEKGDPGLPG PMGLSGLQGP TGPVGPKGEN GSAGEPGPKG ERGLSGPPGL PGIPGPAGKE GPSGKQGNIG PQGKPGPKGE AGPKGEVGAP GMQGSTGAKG STGPKGERGA PGVQGAPGNA GAAGPAGPAG PQGAPGSRGP PGLKGDRGVP GDRGIKGESG LPDSAALRQQ MEALKGKLQR LEVAFSHYQK AALFPDGRSV GDKIFRTADS EKPFEDAQEM CKQAGGQLAS PRSATENAAI QQLITAHNKA AFLSMTDVGT EGKFTYPTGE PLVYSNWAPG EPNNNGGAEN CVEIFTNGQW NDKACGEQRL VICEF |
| Specificity: | Ala20-Phe374 |
| Purity: | > 95 % by SDS-PAGE. |
| Sterility: | 0.22 µm filtered |
| Endotoxin Level: | <0.1EU/µg |

## Target Details

| | |
|---|---|
| Target: | SFTPD |
| Alternative Name: | Lung surfactant protein D/SFTPD (SFTPD Products) |
| Background: | Description: Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides, it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.<br>Name: SP-D,Sfpd,Sftp4,AI573415,SFTPD |
| Gene ID: | 20390 |
| UniProt: | P50404 |

## Application Details

| | |
|---|---|
| Restrictions: | For Research Use only |

## Handling

| | |
|---|---|
| Format: | Lyophilized |
| Reconstitution: | Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid votex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1 % BSA, 5 % HSA, 10 % FBS or 5 % Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
| Buffer: | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4. |
| Storage: | -20 °C,-80 °C |

## Handling

| | |
|---|---|
| Storage Comment: | Store the lyophilized protein at -20°C to -80°C for long term.\|After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week. |